Argos passes on IPO and raises $25m Series D to fund personalized cancer immunotherapy

Rather than pursue an initial public offering this year, personalized cancer immunotherapy developer Argos Therapeutics raised $25 million in a Series D financing round to fund its Phase III ADAPT clinical trial for AGS-003 in metastatic renal cell carcinoma (mRCC) through mid-2013 when it will have interim data to support additional venture capital investment, an IPO or a partnership.